Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer

Progress in Lipid Research

Volumn 53, Issue 1, 2014, Pages 108-123

  Zhang, Guodong ^a,b   Kodani, Sean ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Cytochrome P450 epoxygenase; Epoxydocosapentaenoic acids; Epoxyeicosatrienoic acids; Soluble epoxide hydrolase

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ARACHIDONIC ACID; CANNABINOID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; DOCOSAHEXAENOIC ACID; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; REGORAFENIB; ROFECOXIB; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; SORAFENIB; TRICLOCARBAN; UNCLASSIFIED DRUG; VASCULOTROPIN; CYTOCHROME P450 EPOXYGENASE; FATTY ACID; SOLUBLE EPOXIDE HYDROLASE; CANNABINOID RECEPTOR; CYTOCHROME P450 2C8; CYTOCHROME P450 2J2; DIHYDROXYICOSATRIENOIC ACID; EPOXYDOCOSAPENTAENOIC ACID; EPOXYEICOSATETRAENOIC ACID; EPOXYGENATED FATTY ACID DERIVATIVE; FATTY ACID DERIVATIVE; I KAPPA B ALPHA; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 2;

ALLODYNIA; ANALGESIC ACTIVITY; ANGIOGENESIS; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; BLOOD VESSEL TONE; BURN; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHRONIC PAIN; DIET SUPPLEMENTATION; DRUG MEGADOSE; DRUG POTENTIATION; EPOXIDATION; EROSION; FATIGUE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL EROSION; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART PROTECTION; HUMAN; HYPERALGESIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IDIOPATHIC DISEASE; INFLAMMATION; INFLAMMATORY PAIN; INTESTINAL BLEEDING; KIDNEY CANCER; LIVER CANCER; LIVER FAILURE; LYMPHANGIOGENESIS; METASTASIS; METASTATIC COLORECTAL CANCER; NEOPLASM; NEUROPATHIC PAIN; NONHUMAN; PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RENAL PROTECTION; RETINA MACULA DEGENERATION; SEPSIS; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TUMOR GROWTH; VASODILATATION; ANIMAL; CHEMISTRY; EPOXYDOCOSAPENTAENOIC ACIDS; EPOXYEICOSATRIENOIC ACIDS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); REVIEW; BIOLOGICAL ACTIVITY; ENZYME INHIBITION; PROTEIN EXPRESSION;

CYTOCHROME P450 EPOXYGENASE; EPOXYDOCOSAPENTAENOIC ACIDS; EPOXYEICOSATRIENOIC ACIDS; SOLUBLE EPOXIDE HYDROLASE;

ANIMALS; FATTY ACIDS; HUMANS; INFLAMMATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PAIN;

EID: 84891603937     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2013.11.003     Document Type: Review

References (211)

1. M.W. Buczynski, D.S. Dumlao, and E.A. Dennis Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology J Lipid Res 50 2009 1015 1038
2. C.D. Funk Prostaglandins and leukotrienes: advances in eicosanoid biology Science 294 2001 1871 1875 (Pubitemid 33101574)
3. D.C. Zeldin Epoxygenase pathways of arachidonic acid metabolism J Biol Chem 276 2001 36059 36062
4. J.D. Imig, and B.D. Hammock Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Nat Rev Drug Discov 8 2009 794 805
5. C. Morisseau, and B.D. Hammock Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health Annu Rev Pharmacol Toxicol 53 2013 37 58
6. J.W. Newman, C. Morisseau, and B.D. Hammock Epoxide hydrolases: their roles and interactions with lipid metabolism Prog Lipid Res 44 2005 1 51 (Pubitemid 40313218)
7. J.L. Blankman, and B.F. Cravatt Chemical probes of endocannabinoid metabolism Pharmacol Rev 65 2013 849 871
8. D.L. Kroetz, and F. Xu Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation Annu Rev Pharmacol Toxicol 45 2005 413 438 (Pubitemid 40261812)
9. J.M. Williams, S. Murphy, M. Burke, and R.J. Roman 20- Hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension J Cardiovasc Pharmacol 56 2010 336 344
10. J. Cheng, J.S. Ou, H. Singh, J.R. Falck, D. Narsimhaswamy, and K.A. Pritchard Jr et al. 20-Hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling Am J Physiol Heart Circ Physiol 294 2008 H1018 H1026
11. T. Ishizuka, J. Cheng, H. Singh, M.D. Vitto, V.L. Manthati, and J.R. Falck et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells J Pharmacol Exp Ther 324 2008 103 110 (Pubitemid 350294158)
12. N. Miyata, and R.J. Roman Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system J Smooth Muscle Res 41 2005 175 193 (Pubitemid 41596358)
13. A.M. Guo, A.S. Arbab, J.R. Falck, P. Chen, P.A. Edwards, and R.J. Roman et al. Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation J Pharmacol Exp Ther 321 2007 18 27 (Pubitemid 46456964)
14. A.M. Guo, J. Sheng, G.M. Scicli, A.S. Arbab, N.L. Lehman, and P.A. Edwards et al. Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo J Pharmacol Exp Ther 327 2008 10 19
15. H.C. Shen, and B.D. Hammock Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications J Med Chem 55 2012 1789 1808
16. H.C. Shen Soluble epoxide hydrolase inhibitors: a patent review Expert Opin Ther Pat. 20 2010 941 956
17. L.M. Arterburn, E.B. Hall, and H. Oken Distribution, interconversion, and dose response of n-3 fatty acids in humans Am J Clin Nutr 83 2006 1467S 1476S (Pubitemid 44713087)
18. K. Kosaka, K. Suzuki, M. Hayakawa, S. Sugiyama, and T. Ozawa Leukotoxin, a linoleate epoxide: its implication in the late death of patients with extensive burns Mol Cell Biochem 139 1994 141 148 (Pubitemid 24371163)
19. Y. Hanaki, H. Kamiya, M. Ohno, M. Hayakawa, S. Sugiyama, and T. Ozawa Leukotoxin, 9, 10-epoxy-12-octadecenoate: a possible responsible factor in circulatory shock and disseminated intravascular coagulation Jpn J Med 30 1991 224 228
20. M. Hayakawa, K. Kosaka, S. Sugiyama, K. Yokoo, H. Aoyama, and Y. Izawa et al. Proposal of leukotoxin, 9,10-epoxy-12-octadecenoate, as a burn toxin Biochem Int 21 1990 573 579 (Pubitemid 20230086)
21. T. Ozawa, M. Hayakawa, K. Kosaka, S. Sugiyama, T. Ogawa, and K. Yokoo et al. Leukotoxin, 9,10-epoxy-12-octadecenoate, as a burn toxin causing adult respiratory distress syndrome Adv Prostaglandin Thromboxane Leukot Res 21B 1991 569 572
22. M.F. Moghaddam, D.F. Grant, J.M. Cheek, J.F. Greene, K.C. Williamson, and B.D. Hammock Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase Nat Med 3 1997 562 566 (Pubitemid 27198657)
23. D.B. Jump The biochemistry of n-3 polyunsaturated fatty acids J Biol Chem 277 2002 8755 8758 (Pubitemid 34952937)
24. D.P. Rose, and J.M. Connolly Omega-3 fatty acids as cancer chemopreventive agents Pharmacol Ther 83 1999 217 244 (Pubitemid 29430123)
25. C.N. Serhan, and N.A. Petasis Resolvins and protectins in inflammation resolution Chem Rev 111 2011 5922 5943
26. D. Bagga, L. Wang, R. Farias-Eisner, J.A. Glaspy, and S.T. Reddy Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion Proc Natl Acad Sci USA 100 2003 1751 1756 (Pubitemid 36254520)
27. M. Szymczak, M. Murray, and N. Petrovic Modulation of angiogenesis by omega-3 polyunsaturated fatty acids is mediated by cyclooxygenases Blood 111 2008 3514 3521
28. P. Sapieha, A. Stahl, J. Chen, M.R. Seaward, K.L. Willett, and N.M. Krah et al. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids Sci Transl Med 3 2011 69ra12
29. C. Arnold, M. Markovic, K. Blossey, G. Wallukat, R. Fischer, and R. Dechend et al. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of omega-3 fatty acids J Biol Chem 285 2010 32720 32733
30. C. Morisseau, B. Inceoglu, K. Schmelzer, H.J. Tsai, S.L. Jinks, and C.M. Hegedus et al. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids J Lipid Res 51 2010 3481 3490
31. D. Ye, D. Zhang, C. Oltman, K. Dellsperger, H.C. Lee, and M. VanRollins Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels J Pharmacol Exp Ther 303 2002 768 776 (Pubitemid 35231254)
32. D. Panigrahy, M.L. Edin, C.R. Lee, S. Huang, D.R. Bielenberg, and C.E. Butterfield et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice J Clin Invest 122 2012 178 191
33. G. Zhang, D. Panigrahy, L.M. Mahakian, J. Yang, J.Y. Liu, and K.S. Stephen Lee et al. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis Proc Natl Acad Sci USA 110 2013 6530 6535
34. J.D. Imig Epoxides and soluble epoxide hydrolase in cardiovascular physiology Physiol Rev 92 2012 101 130
35. J.D. Imig Targeting epoxides for organ damage in hypertension J Cardiovasc Pharmacol 56 2010 329 335
36. I. Fleming Cytochrome p450 and vascular homeostasis Circ Res 89 2001 753 762
37. J.H. Capdevila, J.R. Falck, and R.W. Estabrook Cytochrome P450 and the arachidonate cascade FASEB J 6 1992 731 736
38. A.C. Lee, and M. Murray Up-regulation of human CYP2J2 in HepG2 cells by butylated hydroxyanisole is mediated by c-Jun and Nrf2 Mol Pharmacol 77 2010 987 994
39. U.R. Michaelis, B. Fisslthaler, E. Barbosa-Sicard, J.R. Falck, I. Fleming, and R. Busse Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis J Cell Sci 118 2005 5489 5498 (Pubitemid 43079290)
40. U.R. Michaelis, N. Xia, E. Barbosa-Sicard, J.R. Falck, and I. Fleming Role of cytochrome P450 2C epoxygenases in hypoxia-induced cell migration and angiogenesis in retinal endothelial cells Invest Ophthalmol Vis Sci 49 2008 1242 1247
41. C.W. Pugh, and P.J. Ratcliffe Regulation of angiogenesis by hypoxia: role of the HIF system Nat Med 9 2003 677 684 (Pubitemid 36749216)
42. S. Kundu, T. Roome, A. Bhattacharjee, K.A. Carnevale, V.P. Yakubenko, and R. Zhang et al. Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo J Lipid Res 54 2013 436 447
43. J.W. Newman, C. Morisseau, T.R. Harris, and B.D. Hammock The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity Proc Natl Acad Sci USA 100 2003 1558 1563 (Pubitemid 36254486)
44. D. Panigrahy, S. Singer, L.Q. Shen, C.E. Butterfield, D.A. Freedman, and E.J. Chen et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis J Clin Invest 110 2002 923 932
45. A. Pozzi, M.R. Ibanez, A.E. Gatica, S. Yang, S. Wei, and S. Mei et al. Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis J Biol Chem 282 2007 17685 17695 (Pubitemid 47100312)
46. D. Ai, Y. Fu, D. Guo, H. Tanaka, N. Wang, and C. Tang et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo Proc Natl Acad Sci USA 104 2007 9018 9023 (Pubitemid 47175429)
47. D. Zhang, X. Xie, Y. Chen, B.D. Hammock, W. Kong, and Y. Zhu Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo Circ Res 110 2012 808 817
48. J.Y. Liu, S.H. Park, C. Morisseau, S.H. Hwang, B.D. Hammock, and R.H. Weiss Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo Mol Cancer Ther 8 2009 2193 2203
49. S.H. Hwang, A.T. Wecksler, G. Zhang, C. Morisseau, L.V. Nguyen, and S.H. Fu et al. Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors Bioorg Med Chem Lett 23 2013 3732 3737
50. K.T. Moreland, J.D. Procknow, R.S. Sprague, J.L. Iverson, A.J. Lonigro, and A.H. Stephenson Cyclooxygenase (COX)-1 and COX-2 participate in 5,6-epoxyeicosatrienoic acid-induced contraction of rabbit intralobar pulmonary arteries J Pharmacol Exp Ther 321 2007 446 454 (Pubitemid 46624502)
51. J.Y. Zhang, C. Prakash, K. Yamashita, and I.A. Blair Regiospecific and enantioselective metabolism of 8,9-epoxyeicosatrienoic acid by cyclooxygenase Biochem Biophys Res Commun 183 1992 138 143
52. T. Homma, J.Y. Zhang, T. Shimizu, C. Prakash, I.A. Blair, and R.C. Harris Cyclooxygenase-derived metabolites of 8,9-epoxyeicosatrienoic acid are potent mitogens for cultured rat glomerular mesangial cells Biochem Biophys Res Commun 191 1993 282 288 (Pubitemid 23222633)
53. K.R. Schmelzer, B. Inceoglu, L. Kubala, I.H. Kim, S.L. Jinks, and J.P. Eiserich et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors Proc Natl Acad Sci USA 103 2006 13646 13651 (Pubitemid 44413961)
54. J.Y. Liu, J. Yang, B. Inceoglu, H. Qiu, A. Ulu, and S.H. Hwang et al. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model Biochem Pharmacol 79 2010 880 887
55. T. Kubota, M. Arita, Y. Isobe, R. Iwamoto, T. Goto, and T. Yoshioka et al. Eicosapentaenoic acid is converted via omega-3 epoxygenation to the anti-inflammatory metabolite 12-hydroxy-17,18-epoxyeicosatetraenoic acid FASEB J 2013
56. X. Fang, T.L. Kaduce, N.L. Weintraub, S. Harmon, L.M. Teesch, and C. Morisseau et al. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition J Biol Chem 276 2001 14867 14874
57. A. Wolk, S.C. Larsson, J.E. Johansson, and P. Ekman Long-term fatty fish consumption and renal cell carcinoma incidence in women JAMA 296 2006 1371 1376 (Pubitemid 44427423)
58. M.N. Hall, J.E. Chavarro, I.M. Lee, W.C. Willett, and J. Ma A 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men Cancer Epidemiol Biomarkers Prev 17 2008 1136 1143
59. T.M. Brasky, J.W. Lampe, J.D. Potter, R.E. Patterson, and E. White Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort Cancer Epidemiol Biomarkers Prev 19 2010 1696 1708
60. S. Kim, D.P. Sandler, J. Galanko, C. Martin, and R.S. Sandler Intake of polyunsaturated fatty acids and distal large bowel cancer risk in whites and African Americans Am J Epidemiol 171 2010 969 979
61. N. Sawada, M. Inoue, M. Iwasaki, S. Sasazuki, T. Shimazu, and T. Yamaji et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma Gastroenterology 142 2012 1468 1475
62. N. Simonsen, P. van't Veer, J.J. Strain, J.M. Martin-Moreno, J.K. Huttunen, and J.F. Navajas et al. Adipose tissue omega-3 and omega-6 fatty acid content and breast cancer in the EURAMIC study. European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer Am J Epidemiol 147 1998 342 352
63. C.M. Alfano, I. Imayama, M.L. Neuhouser, J.K. Kiecolt-Glaser, A.W. Smith, and K. Meeske et al. Fatigue, inflammation, and omega-3 and omega-6 fatty acid intake among breast cancer survivors J Clin Oncol 30 2012 1280 1287
64. E. Cho, S. Hung, W.C. Willett, D. Spiegelman, E.B. Rimm, and J.M. Seddon et al. Prospective study of dietary fat and the risk of age-related macular degeneration Am J Clin Nutr 73 2001 209 218 (Pubitemid 32109848)
65. J.M. Seddon, S. George, and B. Rosner Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the us twin study of age-related macular degeneration Arch Ophthalmol 124 2006 995 1001 (Pubitemid 44036322)
66. J.P. SanGiovanni, E.Y. Chew, T.E. Clemons, M.D. Davis, F.L. Ferris 3rd, and G.R. Gensler et al. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report No. 20 Arch Ophthalmol 125 2007 671 679 (Pubitemid 46762729)
67. K.M. Connor, J.P. SanGiovanni, C. Lofqvist, C.M. Aderman, J. Chen, and A. Higuchi et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis Nat Med 13 2007 868 873 (Pubitemid 47038185)
68. J.H. Dwyer, H. Allayee, K.M. Dwyer, J. Fan, H. Wu, and R. Mar et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis N Engl J Med 350 2004 29 37 (Pubitemid 38032181)
69. D. Lucas, S. Goulitquer, J. Marienhagen, M. Fer, Y. Dreano, and U. Schwaneberg et al. Stereoselective epoxidation of the last double bond of polyunsaturated fatty acids by human cytochromes P450 J Lipid Res 51 2010 1125 1133
70. D. Schwarz, P. Kisselev, S.S. Ericksen, G.D. Szklarz, A. Chernogolov, and H. Honeck et al. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid Biochem Pharmacol 67 2004 1445 1457 (Pubitemid 38388207)
71. E. Barbosa-Sicard, M. Markovic, H. Honeck, B. Christ, D.N. Muller, and W.H. Schunck Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily Biochem Biophys Res Commun 329 2005 1275 1281 (Pubitemid 40568707)
72. G.C. Shearer, W.S. Harris, T.L. Pedersen, and J.W. Newman Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters J Lipid Res 51 2010 2074 2081
73. A.H. Keenan, T.L. Pedersen, K. Fillaus, M.K. Larson, G.C. Shearer, and J.W. Newman Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers J Lipid Res 53 2012 1662 1669
74. A. Zivkovic, J. Yang, K. Georgi, C. Hegedus, M. Nording, and A. O'Sullivan et al. Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations Metabolomics 8 2012 1102 1113
75. D. Wang, T. Hirase, T. Nitto, M. Soma, and K. Node Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor gamma in endothelial cells J Cardiol 54 2009 368 374
76. T. Fromel, B. Jungblut, J. Hu, C. Trouvain, E. Barbosa-Sicard, and R. Popp et al. Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols Proc Natl Acad Sci USA 109 2012 9995 10000
77. G.K. Hansson Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 2005 1685 1695
78. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874 (Pubitemid 36019640)
79. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867 (Pubitemid 36019639)
80. F.A. Kuehl Jr., and R.W. Egan Prostaglandins, arachidonic acid, and inflammation Science 210 1980 978 984 (Pubitemid 11168243)
81. J.R. Vane, Y.S. Bakhle, and R.M. Botting Cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 38 1998 97 120 (Pubitemid 28231490)
82. L.J. Marnett The COXIB experience: a look in the rearview mirror Annu Rev Pharmacol Toxicol 49 2009 265 290
83. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, and K. Horgan et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 352 2005 1092 1102 (Pubitemid 40365350)
84. G.A. FitzGerald Coxibs and cardiovascular disease N Engl J Med 351 2004 1709 1711
85. K. Node, Y. Huo, X. Ruan, B. Yang, M. Spiecker, and K. Ley et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids Science 285 1999 1276 1279 (Pubitemid 29398616)
86. C. Morin, M. Sirois, V. Echave, M.M. Gomes, and E. Rousseau EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17 Am J Respir Cell Mol Biol 38 2008 192 201 (Pubitemid 351162841)
87. Y. Deng, M.L. Edin, K.N. Theken, R.N. Schuck, G.P. Flake, and M.A. Kannon et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice FASEB J 25 2011 703 713
88. J. Bystrom, J.A. Wray, M.C. Sugden, M.J. Holness, K.E. Swales, and T.D. Warner et al. Endogenous epoxygenases are modulators of monocyte/macrophage activity PLoS One 6 2011 e26591
89. W. Kozak, D.M. Aronoff, O. Boutaud, and A. Kozak 11,12- Epoxyeicosatrienoic acid attenuates synthesis of prostaglandin E2 in rat monocytes stimulated with lipopolysaccharide Exp Biol Med (Maywood) 228 2003 786 794 (Pubitemid 37169263)
90. W.G. Sanders, C. Morisseau, B.D. Hammock, A.K. Cheung, and C.M. Terry Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor Am J Physiol Cell Physiol 303 2012 C278 C290
91. K.R. Schmelzer, L. Kubala, J.W. Newman, I.H. Kim, J.P. Eiserich, and B.D. Hammock Soluble epoxide hydrolase is a therapeutic target for acute inflammation Proc Natl Acad Sci USA 102 2005 9772 9777 (Pubitemid 40993644)
92. K.R. Smith, K.E. Pinkerton, T. Watanabe, T.L. Pedersen, S.J. Ma, and B.D. Hammock Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor Proc Natl Acad Sci USA 102 2005 2186 2191 (Pubitemid 40262033)
93. A.A. Elmarakby, J. Faulkner, M. Al-Shabrawey, M.H. Wang, K.R. Maddipati, and J.D. Imig Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes Am J Physiol Regul Integr Comp Physiol 301 2011 R1307 R1317
94. J.Y. Liu, H. Qiu, C. Morisseau, S.H. Hwang, H.J. Tsai, and A. Ulu et al. Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model Toxicol Appl Pharmacol 255 2011 200 206
95. Y. Liu, H. Dang, D. Li, W. Pang, B.D. Hammock, and Y. Zhu Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice PLoS One 7 2012 e39165
96. M. Manhiani, J.E. Quigley, S.F. Knight, S. Tasoobshirazi, T. Moore, and M.W. Brands et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension Am J Physiol Renal Physiol 297 2009 F740 F748
97. M. Revermann, M. Schloss, E. Barbosa-Sicard, A. Mieth, S. Liebner, and C. Morisseau et al. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice Arterioscler Thromb Vasc Biol 30 2010 909 914
98. S. Sturlan, G. Oberhuber, B.G. Beinhauer, B. Tichy, S. Kappel, and J. Wang et al. Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development Carcinogenesis 22 2001 665 671 (Pubitemid 32288669)
99. W. Zhang, A.L. Yang, J. Liao, H. Li, H. Dong, and Y.T. Chung et al. Soluble epoxide hydrolase gene deficiency or inhibition attenuates chronic active inflammatory bowel disease in IL-10(-/-) mice Dig Dis Sci 57 2012 2580 2591
100. W. Zhang, J. Liao, H. Li, H. Dong, H. Bai, and A. Yang et al. Reduction of inflammatory bowel disease-induced tumor development in IL-10 knockout mice with soluble epoxide hydrolase gene deficiency Mol Carcinog 52 2013 726 738
101. B.B. Davis, J.Y. Liu, D.J. Tancredi, L. Wang, S.I. Simon, and B.D. Hammock et al. The anti-inflammatory effects of soluble epoxide hydrolase inhibitors are independent of leukocyte recruitment Biochem Biophys Res Commun 410 2011 494 500
102. K.L. Fife, Y. Liu, K.R. Schmelzer, H.J. Tsai, I.H. Kim, and C. Morisseau et al. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation J Pharmacol Exp Ther 327 2008 707 715
103. P.A. Baeuerle, and T. Henkel Function and activation of NF-kappa B in the immune system Annu Rev Immunol 12 1994 141 179
104. Y. Liu, Y. Zhang, K. Schmelzer, T.S. Lee, X. Fang, and Y. Zhu et al. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase Proc Natl Acad Sci USA 102 2005 16747 16752 (Pubitemid 41688848)
105. D. Xu, N. Li, Y. He, V. Timofeyev, L. Lu, and H.J. Tsai et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors Proc Natl Acad Sci USA 103 2006 18733 18738 (Pubitemid 44913479)
106. V.Y. Ng, Y. Huang, L.M. Reddy, J.R. Falck, E.T. Lin, and D.L. Kroetz Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha Drug Metab Dispos 35 2007 1126 1134 (Pubitemid 46956433)
107. J. Wray, and D. Bishop-Bailey Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology Exp Physiol 93 2008 148 154 (Pubitemid 350293969)
108. J.A. Wray, M.C. Sugden, D.C. Zeldin, G.K. Greenwood, S. Samsuddin, and L. Miller-Degraff et al. The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo PLoS One 4 2009 e7421
109. B. Inceoglu, S.L. Jinks, A. Ulu, C.M. Hegedus, K. Georgi, and K.R. Schmelzer et al. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways Proc Natl Acad Sci USA 105 2008 18901 18906
110. Y. Cheng, S.C. Austin, B. Rocca, B.H. Koller, T.M. Coffman, and T. Grosser et al. Role of prostacyclin in the cardiovascular response to thromboxane A(2) Science 296 2002 539 541 (Pubitemid 34408674)
111. R. Morphy, and Z. Rankovic Designed multiple ligands. an emerging drug discovery paradigm J Med Chem 48 2005 6523 6543 (Pubitemid 41504710)
112. S.H. Hwang, K.M. Wagner, C. Morisseau, J.Y. Liu, H. Dong, and A.T. Wecksler et al. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase J Med Chem 54 2011 3037 3050
113. D. Bouhassira, M. Lanteri-Minet, N. Attal, B. Laurent, and C. Touboul Prevalence of chronic pain with neuropathic characteristics in the general population Pain 136 2008 380 387 (Pubitemid 351680253)
114. D.J. Gaskin, and P. Richard The economic costs of pain in the United States J Pain 13 2012 715 724
115. H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment Eur J Pain 10 2006 287 333
116. B. Inceoglu, K. Schmelzer, C. Morisseau, S.L. Jinks, and B.D. Hammock Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs) Prostaglandins Other Lipid Mediat 82 2007 42 49 (Pubitemid 44880165)
117. K. Wagner, B. Inceoglu, S.S. Gill, and B.D. Hammock Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: novel mediators of pain reduction J Agric Food Chem 59 2011 2816 2824
118. K. Wagner, B. Inceoglu, and B.D. Hammock Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception Prostaglandins Other Lipid Mediat 96 2011 76 83
119. B. Inceoglu, S.L. Jinks, K.R. Schmelzer, T. Waite, I.H. Kim, and B.D. Hammock Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain Life Sci 79 2006 2311 2319 (Pubitemid 44666069)
120. B. Inceoglu, K. Wagner, J. Yang, A. Bettaieb, N.H. Schebb, and S.H. Hwang et al. Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes Proc Natl Acad Sci USA 109 2012 11390 11395
121. B. Inceoglu, K. Wagner, N.H. Schebb, C. Morisseau, S.L. Jinks, and A. Ulu et al. Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP Proc Natl Acad Sci USA 108 2011 5093 5097
122. C. Brenneis, M. Sisignano, O. Coste, K. Altenrath, M.J. Fischer, and C. Angioni et al. Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation Mol Pain 7 2011 78
123. A. Luria, A. Bettaieb, Y. Xi, G.-J. Shieh, H.-C. Liu, and H. Inoue et al. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance Proc Natl Acad Sci USA 108 2011 9038 9043
124. H. Watanabe, J. Vriens, J. Prenen, G. Droogmans, T. Voets, and B. Nilius Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels Nature 424 2003 434 438 (Pubitemid 36917492)
125. D.G. Demuth, and A. Molleman Cannabinoid signalling Life Sci 78 2006 549 563 (Pubitemid 41785760)
126. V. Di Marzo Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7 2008 438 455 (Pubitemid 351649182)
127. M.M. Ibrahim, H. Deng, A. Zvonok, D.A. Cockayne, J. Kwan, and H.P. Mata et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS Proc Natl Acad Sci USA 100 2003 10529 10533 (Pubitemid 37071912)
128. A.G. Hohmann, J.N. Farthing, A.M. Zvonok, and A. Makriyannis Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin J Pharmacol Exp Ther 308 2004 446 453 (Pubitemid 38134203)
129. G.M. Reis, D. Pacheco, A.C. Perez, A. Klein, M.A. Ramos, and I.D. Duarte Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of the cannabinoid receptor agonist anandamide Life Sci 85 2009 351 356
130. N.T. Snider, J.A. Nast, L.A. Tesmer, and P.F. Hollenberg A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist Mol Pharmacol 75 2009 965 972
131. M. Terashvili, L.F. Tseng, H.E. Wu, J. Narayanan, L.M. Hart, and J.R. Falck et al. Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of beta-endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray J Pharmacol Exp Ther 326 2008 614 622
132. J.L. Conroy, C. Fang, J. Gu, S.O. Zeitlin, W. Yang, and J. Yang et al. Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling Nat Neurosci 13 2010 284 286
133. M.M. Heinricher, J.J. Maire, D. Lee, J.W. Nalwalk, and L.B. Hough Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor J Neurophysiol 104 2010 3222 3230
134. L.B. Hough, J.W. Nalwalk, J. Yang, J.L. Conroy, M.A. VanAlstine, and W. Yang et al. Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic Pain 152 2011 878 887
135. X. Wang, C.L. Shen, M.T. Dyson, X. Yin, R.B. Schiffer, and P. Grammas et al. The involvement of epoxygenase metabolites of arachidonic acid in cAMP-stimulated steroidogenesis and steroidogenic acute regulatory protein gene expression J Endocrinol 190 2006 871 878 (Pubitemid 44560260)
136. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
137. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 2007 273 286 (Pubitemid 46505878)
138. P.J. Rosenfeld, D.M. Brown, J.S. Heier, D.S. Boyer, P.K. Kaiser, and C.Y. Chung et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431 (Pubitemid 44511557)
139. A.W. Griffioen, and G. Molema Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation Pharmacol Rev 52 2000 237 268 (Pubitemid 30368433)
140. D. Wang, and R.N. Dubois Eicosanoids and cancer Nat Rev Cancer 10 2010 181 193
141. D. Panigrahy, A. Kaipainen, E.R. Greene, and S. Huang Cytochrome P450-derived eicosanoids: the neglected pathway in cancer Cancer Metastasis Rev 29 2010 723 735
142. D.H. Munzenmaier, and D.R. Harder Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release Am J Physiol Heart Circ Physiol 278 2000 H1163 H1167
143. D. Panigrahy, E.R. Greene, A. Pozzi, D.W. Wang, and D.C. Zeldin EET signaling in cancer Cancer Metastasis Rev 30 2011 525 540
144. I. Fleming Epoxyeicosatrienoic acids, cell signaling and angiogenesis Prostaglandins Other Lipid Mediat 82 2007 60 67 (Pubitemid 44880162)
145. M. Potente, B. Fisslthaler, R. Busse, and I. Fleming 11,12- Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1 J Biol Chem 278 2003 29619 29625 (Pubitemid 36962345)
146. J. Ma, L. Zhang, W. Han, T. Shen, C. Ma, and Y. Liu et al. Activation of JNK/c-Jun is required for the proliferation, survival, and angiogenesis induced by EET in pulmonary artery endothelial cells J Lipid Res 53 2012 1093 1105
147. B. Zhang, H. Cao, and G.N. Rao Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15- epoxyeicosatrienoic acid-induced angiogenesis J Biol Chem 281 2006 905 914
148. U.R. Michaelis, B. Fisslthaler, M. Medhora, D. Harder, I. Fleming, and R. Busse Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR) FASEB J 17 2003 770 772
149. G. Yan, S. Chen, B. You, and J. Sun Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids Cardiovasc Res 78 2008 308 314 (Pubitemid 351556100)
150. A. Pozzi, I. Macias-Perez, T. Abair, S. Wei, Y. Su, and R. Zent et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids J Biol Chem 280 2005 27138 27146 (Pubitemid 41040752)
151. M. Medhora, J. Daniels, K. Mundey, B. Fisslthaler, R. Busse, and E.R. Jacobs et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells Am J Physiol Heart Circ Physiol 284 2003 H215 H224
152. A.C. Webler, R. Popp, T. Korff, U.R. Michaelis, C. Urbich, and R. Busse et al. Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4 Arterioscler Thromb Vasc Biol 28 2008 1123 1129
153. U.R. Michaelis, J.R. Falck, R. Schmidt, R. Busse, and I. Fleming Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells Arterioscler Thromb Vasc Biol 25 2005 321 326 (Pubitemid 40189152)
154. S.Y. Cheranov, M. Karpurapu, D. Wang, B. Zhang, R.C. Venema, and G.N. Rao An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis Blood 111 2008 5581 5591
155. A.L. Sander, H. Jakob, K. Sommer, C. Sadler, I. Fleming, and I. Marzi et al. Cytochrome P450-derived epoxyeicosatrienoic acids accelerate wound epithelialization and neovascularization in the hairless mouse ear wound model Langenbecks Arch Surg 396 2011 1245 1253
156. D. Panigrahy, B.T. Kalish, S. Huang, D.R. Bielenberg, H.D. Le, and J. Yang et al. Epoxyeicosanoids promote organ and tissue regeneration Proc Natl Acad Sci USA 110 2013 13528 13533
157. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676 (Pubitemid 36749215)
158. A.C. Webler, U.R. Michaelis, R. Popp, E. Barbosa-Sicard, A. Murugan, and J.R. Falck et al. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis Am J Physiol Cell Physiol 295 2008 C1292 C1301
159. S. Yang, S. Wei, A. Pozzi, and J.H. Capdevila The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis Arch Biochem Biophys 489 2009 82 91
160. J.K. Chen, J.R. Falck, K.M. Reddy, J. Capdevila, and R.C. Harris Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells J Biol Chem 273 1998 29254 29261 (Pubitemid 28507627)
161. J.K. Chen, J. Capdevila, and R.C. Harris Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells Proc Natl Acad Sci USA 99 2002 6029 6034 (Pubitemid 34493259)
162. K. Nithipatikom, D.M. Brody, A.T. Tang, V.L. Manthati, J.R. Falck, and C.L. Williams et al. Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists Cancer Sci 101 2010 2629 2636
163. S. Yang, L. Lin, J.X. Chen, C.R. Lee, J.M. Seubert, and Y. Wang et al. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways Am J Physiol Heart Circ Physiol 293 2007 H142 H151
164. J.G. Jiang, C.L. Chen, J.W. Card, S. Yang, J.X. Chen, and X.N. Fu et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors Cancer Res 65 2005 4707 4715 (Pubitemid 40740807)
165. J.G. Jiang, Y.G. Ning, C. Chen, D. Ma, Z.J. Liu, and S. Yang et al. Cytochrome p450 epoxygenase promotes human cancer metastasis Cancer Res 67 2007 6665 6674 (Pubitemid 47105512)
166. C. Chen, X. Wei, X. Rao, J. Wu, S. Yang, and F. Chen et al. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth J Pharmacol Exp Ther 336 2011 344 355
167. R. Mitra, Z. Guo, M. Milani, C. Mesaros, M. Rodriguez, and J. Nguyen et al. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (+/-)-14,15-epoxyeicosatrienoic acid (EET) J Biol Chem 286 2011 17543 17559
168. G.I. Murray, S. Patimalla, K.N. Stewart, I.D. Miller, and S.D. Heys Profiling the expression of cytochrome P450 in breast cancer Histopathology 57 2010 202 211
169. F.P. Guengerich, and C.G. Turvy Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples J Pharmacol Exp Ther 256 1991 1189 1194
170. J. Leclerc, G. Tournel, E. Courcot-Ngoubo Ngangue, N. Pottier, and J.J. Lafitte et al. Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers Biochimie 92 2010 292 306
171. A.I. Goodman, M. Choudhury, J.L. da Silva, M.L. Schwartzman, and N.G. Abraham Overexpression of the heme oxygenase gene in renal cell carcinoma Proc Soc Exp Biol Med 214 1997 54 61
172. A.E. Enayetallah, R.A. French, and D.F. Grant Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms J Mol Histol 37 2006 133 141
173. A. Ulu, T.R. Harris, C. Morisseau, C. Miyabe, H. Inoue, and G. Schuster et al. Anti-inflammatory Effects of Omega-3 Polyunsaturated Fatty Acids and Soluble Epoxide Hydrolase Inhibitors in Angiotensin-II Dependent Hypertension J Cardiovasc Pharmacol 62 2013 285 297
174. C. Morin, M. Sirois, V. Echave, R. Albadine, and E. Rousseau 17,18-Epoxyeicosatetraenoic acid targets PPARgamma and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase Am J Respir Cell Mol Biol 43 2010 564 575
175. H.X. Chen, and J.N. Cleck Adverse effects of anticancer agents that target the VEGF pathway Nat Rev Clin Oncol 6 2009 465 477
176. M.C. Morris, F. Sacks, and B. Rosner Does fish oil lower blood pressure? A meta-analysis of controlled trials Circulation 88 1993 523 533 (Pubitemid 23228051)
177. K.H. Bonaa, K.S. Bjerve, B. Straume, I.T. Gram, and D. Thelle Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromso study N Engl J Med 322 1990 795 801 (Pubitemid 20094142)
178. T. Hoshi, B. Wissuwa, Y. Tian, N. Tajima, R. Xu, and M. Bauer et al. Omega-3 fatty acids lower blood pressure by directly activating large-conductance Ca(2)(+)-dependent K(+) channels Proc Natl Acad Sci USA 110 2013 4816 4821
179. K. Alitalo, T. Tammela, and T.V. Petrova Lymphangiogenesis in development and human disease Nature 438 2005 946 953 (Pubitemid 43093960)
180. J. Hu, R. Popp, and I. Fleming Genetic deletion and pharmacological inhibition of the soluble epoxide hydrolase attenuate angiogenesis in the murine retina Acta Physiol 201 Suppl. 682 2011 P045
181. P.H. Cui, N. Petrovic, and M. Murray The omega-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down-regulation Br J Pharmacol 162 2011 1143 1155
182. M.S. O'Reilly, L. Holmgren, Y. Shing, C. Chen, R.A. Rosenthal, and M. Moses et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 79 1994 315 328 (Pubitemid 24324921)
183. P.S. Steeg Tumor metastasis: mechanistic insights and clinical challenges Nat Med 12 2006 895 904 (Pubitemid 44175140)
184. J.R. Falck, G. Wallukat, N. Puli, M. Goli, C. Arnold, and A. Konkel et al. 17(R),18(S)-epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: structure-activity relationships and stable analogues J Med Chem 54 2011 4109 4118
185. A.G. Guedes, C. Morisseau, A. Sole, J.H. Soares, A. Ulu, and H. Dong et al. Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis Vet Anaesth Analg 40 2013 440 448
186. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Siebels et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
187. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
188. G.D. Demetri, P. Reichardt, Y.K. Kang, J.Y. Blay, P. Rutkowski, and H. Gelderblom et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 295 302
189. A. Grothey, E. Van Cutsem, A. Sobrero, S. Siena, A. Falcone, and M. Ychou et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
190. S.M. Wilhelm, J. Dumas, L. Adnane, M. Lynch, C.A. Carter, and G. Schutz et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int J Cancer 129 2011 245 255
191. A.R. Parrish, G. Chen, R.C. Burghardt, T. Watanabe, C. Morisseau, and B.D. Hammock Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase Cell Biol Toxicol 25 2009 217 225
192. Y. Liu, H.K. Webb, H. Fukushima, J. Micheli, S. Markova, and J.L. Olson et al. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor kappaB signaling J Pharmacol Exp Ther 341 2012 725 734
193. P.Y. Wong, K.T. Lin, Y.T. Yan, D. Ahern, J. Iles, and S.Y. Shen et al. 14(R),15(S)-epoxyeicosatrienoic acid (14(R),15(S)-EET) receptor in guinea pig mononuclear cell membranes J Lipid Mediat 6 1993 199 208
194. W. Yang, V.R. Tuniki, S. Anjaiah, J.R. Falck, C.J. Hillard, and W.B. Campbell Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14,15-epoxyeicosa-8(Z)- enoic acid J Pharmacol Exp Ther 324 2008 1019 1027 (Pubitemid 351397827)
195. C.M. Alfano, I. Imayama, M.L. Neuhouser, J.K. Kiecolt-Glaser, A.W. Smith, and K. Meeske et al. Fatigue, inflammation, and omega-3 and omega-6 fatty acid intake among breast cancer survivors J Clin Oncol 30 2012 1280 1287
196. P.M. Kris-Etherton, W.S. Harris, and L.J. Appel American Heart Association. Nutrition C. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease Circulation 106 2002 2747 2757
197. C.M. Albert, H. Campos, M.J. Stampfer, P.M. Ridker, J.E. Manson, and W.C. Willett et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death N Engl J Med 346 2002 1113 1118 (Pubitemid 34984601)
198. A.P. Simopoulos Omega-3 fatty acids in inflammation and autoimmune diseases J Am Coll Nutr 21 2002 495 505 (Pubitemid 36026261)
199. C.H. MacLean, S.J. Newberry, W.A. Mojica, P. Khanna, A.M. Issa, and M.J. Suttorp et al. Effects of omega-3 fatty acids on cancer risk: a systematic review JAMA 295 2006 403 415 (Pubitemid 43144977)
200. E.C. Rizos, E.E. Ntzani, E. Bika, M.S. Kostapanos, and M.S. Elisaf Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis JAMA 308 2012 1024 1033
201. T.M. Brasky, A.K. Darke, X. Song, C.M. Tangen, P.J. Goodman, and I.M. Thompson et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial J Natl Cancer Inst 105 2013 1132 1141
202. M.L. Nording, J. Yang, K. Georgi, C. Hegedus Karbowski, J.B. German, and R.H. Weiss et al. Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acids PLoS One 8 2013 e76575
203. I.M. Berquin, Y. Min, R. Wu, J. Wu, D. Perry, and J.M. Cline et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids J Clin Invest 117 2007 1866 1875 (Pubitemid 47036320)
204. A.W. Dreisbach, S. Japa, A. Sigel, M.B. Parenti, A.E. Hess, and S.L. Srinouanprachanh et al. The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension Am J Hypertens 18 2005 1276 1281 (Pubitemid 41400194)
205. M. Spiecker, H. Darius, T. Hankeln, M. Soufi, A.M. Sattler, and J.R. Schaefer et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2 Circulation 110 2004 2132 2136 (Pubitemid 39372490)
206. M. Fornage, E. Boerwinkle, P.A. Doris, D. Jacobs, K. Liu, and N.D. Wong Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study Circulation 109 2004 335 339 (Pubitemid 38133900)
207. C.R. Lee, K.E. North, M.S. Bray, M. Fornage, J.M. Seubert, and J.W. Newman et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study Hum Mol Genet 15 2006 1640 1649 (Pubitemid 43904830)
208. Q. Wei, P.A. Doris, M.V. Pollizotto, E. Boerwinkle, D.R. Jacobs Jr., and D.S. Siscovick et al. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: interaction with cigarette smoking Atherosclerosis 190 2007 26 34 (Pubitemid 44920229)
209. B.D. Przybyla-Zawislak, P.K. Srivastava, J. Vazquez-Matias, H.W. Mohrenweiser, J.E. Maxwell, and B.D. Hammock et al. Polymorphisms in human soluble epoxide hydrolase Mol Pharmacol 64 2003 482 490 (Pubitemid 36910013)
210. P.K. Srivastava, V.K. Sharma, D.S. Kalonia, and D.F. Grant Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure Arch Biochem Biophys 427 2004 164 169 (Pubitemid 38757765)
211. S.H. Zeisel, R.A. Waterland, J.M. Ordovas, D.M. Muoio, W. Jia, and A. Fodor Highlights of the 2012 Research Workshop: Using nutrigenomics and metabolomics in clinical nutrition research JPEN J Parenter Enteral Nutr 37 2013 190 200